{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'The secondary endpoints \"QMG responders after the first Treatment Cycle in AChR-Ab seropositive patients,', 'MG-ADL responders after the first Treatment Cycle in the overall population, and early MG-ADL responders', 'after the first Treatment Cycle in AChR-Ab seropositive patients\" will be analyzed using the same', 'methodology as for the primary endpoint. The secondary endpoint \"Percentage of time patients have a', 'clinically meaningful improvement in total MG-ADL score in AChR-Ab seropositive patients\" will be', 'analyzed using an analysis of covariance (ANCOVA) model with terms for randomized treatment and', 'Baseline total MG-ADL score as a covariate; the model will be stratified for the stratification variables. The', 'secondary endpoint \"Time from TC1V5 to qualification for re-treatment monitored by total MG-ADL score in', 'AChR-Ab seropositive patients\" will be analyzed using Kaplan-Meier time to event analysis (stratified log-', 'rank test), stratified for the stratification variables.', 'The continuous endpoints, i.e., total score changes from Baseline, between treatment groups at a specific day', 'post-Baseline (SEB and TCnB), will be analyzed by means of Mixed Models for Repeated Measurements', '(MMRM). Baseline total score values will be included in the MMRM as well as the stratification factors.', 'Moreover, summary statistics will be provided for all continuous endpoints.', 'Frequency tables will be made for all binary variables, including AEs.', 'argenx BVBA', 'Confidential', 'Page 27 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Table 1', 'General Schedule of Assessments', 'End of Study,', 'ITC', 'Assessment', 'Screening', 'Treatment Period', 'Follow-up (FU) Period', 'Early', 'Unscheduled', 'Period', 'Discontinuation', 'Visits Treatment', 'TC1V1', 'SCR', 'TC1V2', 'TC1V3', 'TC1V4', 'TC1V5', 'TC1V6', 'TC1V7', 'TC1V8', 'TC1V9', 'Cycle 1', '(SEB)', 'Trial Day (Visit', 'Day-14', '1', '8+1', '15+1', '22+1', '29+1', '36+1', '43+1', '50+1', '57+1', 'ITCnVn', 'EoS/ED', 'UNS\"', 'Window)', 'to 1', 'Visits Subsequent', 'TC NV2', 'TC nV7', 'TC ,V8', 'TC ,VV', 'Treatment Cycle(s)b', '(TCnB)', 'Trial Day (Visit', '(X+7)', '(X+14)', '(X+21)', '(X+28)', '(X+35)', '(X+42)', '(X+49)', '(X+56)', 'x', 'Y=2', '182+3', 'Window)', '1', '1', '1', '1', '1', '1', '1', '1', 'EoTY', 'Informed consent', 'X', 'Inclusion/exclusion', 'X', 'X', 'criteria', 'Medical/surgical history', 'X', 'Demographic', 'characteristics', 'Randomizationd', 'X', 'MG-ADLe', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'QMGe', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MGCe', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'EQ-5D-5Le', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MG-QoL15re', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Suicidality assessment', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Physical examination', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Height and weighth', 'X', 'Vital signs', 'X', 'X', 'X', 'X', 'X', 'X', 'ECG', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Clinical laboratory testsk', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'AChR-/MuSK-antibody', 'X', 'serotype', 'Urinalysis\u00b9', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'argenx BVBA', 'Confidential', 'Page 28 of 110']\n\n###\n\n", "completion": "END"}